Exploratory Study of Breast Cancer With ABY025 (ABY0125)

Biomedical Radiation Sciences

Status and phase: Completed; Phase 2; Phase 1

Conditions: Breast Cancer

Treatments: Drug: 111-In-ABY-025

Study type: Interventional

Funder types: Other

Identifiers

NCT01216033

111InABY025

Details and patient eligibility

About

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Enrollment: 7 patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• female age >20 years
• one or more known metastases localizations

Exclusion criteria

• other critical disease than breast cancer
• age ≤ 20 years

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)